Dorothy Keefe
Cancer Australia, NSW, Australia
- This delegate is contactable by email.
- This delegate is presenting an abstract at this event.
Professor Keefe is the CEO of Cancer Australia, Australia’s national cancer agency. She is a medical oncologist with a long-term research interest in Supportive Care in Cancer. She has led cancer services at hospital, regional and state levels, and is passionate about health reform and patient-centred care. She has a Master’s degree in Medical Leadership and a strong interest in advocacy, career development and mentoring.
Presentations this author is a contributor to:
The new selective GLP-2 receptor agonist, Elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. (#224)
3:00 PM
Bronwen Mayo
Poster discussion 1
Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. (#225)
3:00 PM
Bronwen Mayo
Poster discussion 1
Assessing the efficacy of ice-cream-formulated iron-saturated lactoferrin and anhydrous milk fat in preventing chemotherapy induced diarrhoea – the ReCharge Study, a randomised phase IIb trial (#127)
4:00 PM
Sarah Benge
Best of the Best Orals - Supportive care
Mucositis and its links to other toxicities in lung cancer (#83)
11:00 AM
Dorothy Keefe
Concurrent Session - Symptom management in lung cancer